INTRODUCTION: Chronic lymphocytic leukemia (CLL) is a B-cell disorder, but it is also associated with abnormalities in T-lymphocyte function. In this study we examine changes in T-lymphocyte CD39 and CD73 expression in patients with CLL. METHODS: Blood samples were drawn from 34 patients with CLL and 31 controls. The cells were stained for CD3, CD4, CD8, CD19, CD39, and CD73 and analyzed by flow cytometry. RESULTS: Overall, patients with CLL had a higher percentage of CD39(+) T lymphocytes than did controls. The percentage of cells expressing CD39 was higher in both CD4(+) cells and CD8(+) cells. Higher CD3/CD39 expression was associated with a later disease stage. No correlations between T-lymphocyte CD39 levels and CD38 or Zap-70 expression were observed. In contrast, the percentage of T lymphocytes and B lymphocytes that expressed CD73 was decreased in patients with CLL. Average B-lymphocyte CD73 expression was decreased in CLL because the majority of CLL clones were CD73. However a minority of CLL clones were CD73(+), and patients with CD73(+) clones tended to have earlier stage disease. CONCLUSION: T-lymphocyte CD39 and CD73 expression may be useful prognostic markers in patients with CLL. Expression of CD73 on the malignant cell population in CLL may be a marker of better prognosis.
INTRODUCTION:Chronic lymphocytic leukemia (CLL) is a B-cell disorder, but it is also associated with abnormalities in T-lymphocyte function. In this study we examine changes in T-lymphocyte CD39 and CD73 expression in patients with CLL. METHODS: Blood samples were drawn from 34 patients with CLL and 31 controls. The cells were stained for CD3, CD4, CD8, CD19, CD39, and CD73 and analyzed by flow cytometry. RESULTS: Overall, patients with CLL had a higher percentage of CD39(+) T lymphocytes than did controls. The percentage of cells expressing CD39 was higher in both CD4(+) cells and CD8(+) cells. Higher CD3/CD39 expression was associated with a later disease stage. No correlations between T-lymphocyte CD39 levels and CD38 or Zap-70 expression were observed. In contrast, the percentage of T lymphocytes and B lymphocytes that expressed CD73 was decreased in patients with CLL. Average B-lymphocyte CD73 expression was decreased in CLL because the majority of CLL clones were CD73. However a minority of CLL clones were CD73(+), and patients with CD73(+) clones tended to have earlier stage disease. CONCLUSION: T-lymphocyte CD39 and CD73 expression may be useful prognostic markers in patients with CLL. Expression of CD73 on the malignant cell population in CLL may be a marker of better prognosis.
Authors: Marc Beyer; Matthias Kochanek; Kamruz Darabi; Alexey Popov; Markus Jensen; Elmar Endl; Percy A Knolle; Roman K Thomas; Michael von Bergwelt-Baildon; Svenja Debey; Michael Hallek; Joachim L Schultze Journal: Blood Date: 2005-05-24 Impact factor: 22.113
Authors: F Rosi; A Tabucchi; F Carlucci; P Galieni; F Lauria; L Zanoni; R Guerranti; E Marinello; R Pagani Journal: Clin Biochem Date: 1998-06 Impact factor: 3.281
Authors: E Dianne Pulte; M Johan Broekman; Kim E Olson; Joan H F Drosopoulos; Jorge R Kizer; Naziba Islam; Aaron J Marcus Journal: Thromb Res Date: 2007-06-07 Impact factor: 3.944
Authors: Karen M Dwyer; Silvia Deaglio; Wenda Gao; David Friedman; Terry B Strom; Simon C Robson Journal: Purinergic Signal Date: 2007-02-06 Impact factor: 3.765
Authors: Dianne Pulte; Kim E Olson; M Johan Broekman; Naziba Islam; Harold S Ballard; Richard R Furman; Ashley E Olson; Aaron J Marcus Journal: J Transl Med Date: 2007-05-04 Impact factor: 5.531
Authors: Gregory M Hayes; Belinda Cairns; Zoia Levashova; Lawrence Chinn; Myra Perez; Jan-Willem Theunissen; Sindy Liao-Chan; Abel Bermudez; Mark R Flory; Karl J Schweighofer; Edward H van der Horst Journal: Am J Transl Res Date: 2015-06-15 Impact factor: 4.060
Authors: Ross J Turner; Nicholas J Geraghty; Jonathan G Williams; Diane Ly; Daniel Brungs; Martin G Carolan; Thomas V Guy; Debbie Watson; Jeremiah F de Leon; Ronald Sluyter Journal: Purinergic Signal Date: 2020-08-05 Impact factor: 3.765
Authors: Sara Serra; Alberto L Horenstein; Tiziana Vaisitti; Davide Brusa; Davide Rossi; Luca Laurenti; Giovanni D'Arena; Marta Coscia; Claudio Tripodo; Giorgio Inghirami; Simon C Robson; Gianluca Gaidano; Fabio Malavasi; Silvia Deaglio Journal: Blood Date: 2011-10-13 Impact factor: 22.113